- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.02. | Medicus Pharma Ltd: Medicus Pharma on Bloomberg World | 568 | ACCESS Newswire | Dr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt Miller PHILADELPHIA, PA / ACCESS Newswire / February 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus"... ► Artikel lesen | |
| MEDICUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 10.02. | New to The Street Signs Six-Part Media Series Featuring Medicus Pharma Ltd. | 292 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / February 10, 2026 / New to The Street, the nationally syndicated, long-form television and digital media platform, today announced it has signed a six-part media... ► Artikel lesen | |
| 10.02. | FDA clears Medicus Pharma's prostate cancer drug for phase 2b trial | 4 | Investing.com | ||
| 10.02. | Medicus Pharma Ltd: Medicus Pharma Receives FDA "Study May Proceed" Clearance For Teverelix Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk | 2.607 | GlobeNewswire (Europe) | PHILADELPHIA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical... ► Artikel lesen | |
| 23.01. | Medicus Pharma Ltd: Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony | 908 | ACCESS Newswire | PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing... ► Artikel lesen | |
| 22.01. | Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix Long-Term Economic and Development Profile | 1 | GlobeNewswire (USA) | ||
| 20.01. | Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026 | 1 | GlobeNewswire (USA) | ||
| 05.01. | Medicus Pharma to present phase 2 data at Biotech Showcase 2026 | 2 | Investing.com | ||
| 05.01. | Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates | 2 | GlobeNewswire (USA) | ||
| 30.12.25 | Medicus Pharma startet "At-the-Market"-Eigenkapitalprogramm über bis zu 15,3 Mio. US-Dollar | 2 | Investing.com Deutsch | ||
| 30.12.25 | Medicus Pharma Ltd. - 8-K, Current Report | - | SEC Filings | ||
| 22.12.25 | Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence Driven Clinical Data Analytics Platform | 625 | ACCESS Newswire | The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute urinary... ► Artikel lesen | |
| 17.12.25 | Medicus Pharma completes patient enrolment for basal cell carcinoma trial | 1 | PMLiVE | ||
| 15.12.25 | Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin | 243 | GlobeNewswire (Europe) | THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) WITH THE FOOD AND DRUG ADMINISTRATION (FDA) IN H1 2026... ► Artikel lesen | |
| 08.12.25 | Medicus Pharma Ltd. - 8-K, Current Report | - | SEC Filings | ||
| 05.12.25 | Medicus Pharma sichert sich 5,1 Mio. US-Dollar durch Optionsschein-Vereinbarung | 2 | Investing.com Deutsch | ||
| 05.12.25 | Medicus Pharma secures $5.1 million from warrant exercise agreement | 1 | Investing.com | ||
| 05.12.25 | Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement | 414 | ACCESS Newswire | Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA / ACCESS Newswire / December 5, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company")... ► Artikel lesen | |
| 01.12.25 | Medicus Pharma Appoints President Carolyn Bonner CFO | 3 | RTTNews | ||
| 01.12.25 | Medicus Pharma appoints Carolyn Bonner as president and CFO | 1 | Investing.com |
1 2 3 4 Weiter >>
70 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 23,350 | -0,17 % | Pfizer, Astellas Pharma Share Positive Data From Bladder Cancer Trial | NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and Astellas Pharma Inc., Friday announced the positive results from the Phase 3 EV-304 clinical trial for PADCEV in combination with Keytruda in... ► Artikel lesen | |
| GILEAD SCIENCES | 125,66 | -0,33 % | Gilead Sciences schlägt zu - 68 Prozent Aufschlag | Die US-amerikanische Biotech-Gesellschaft Gilead Sciences will sich im Bereich der Onkologie verstärken. Mit der geplanten Übernahme von Arcellx erwirbt das Unternehmen die volle Kontrolle über eine... ► Artikel lesen | |
| ELI LILLY | 889,90 | -0,11 % | Opening Bell: Coca-Cola, Nvidia, Eli Lilly, Novo Nordisk, Vistra Energy, Energy Fuels | An der Wall Street richtet sich die Aufmerksamkeit mal wieder auf die Zollpolitik von Donald Trump. Der Supreme Court hatte am Freitag die bisherigen Maßnahmen gekippt. Trump mit neuen Zöllen unter... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 420,00 | -0,11 % | Vertex Pharmaceuticals Inc. Reports Rise In Q4 Bottom Line | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) reported earnings for its fourth quarter that Increases, from last yearThe company's earnings came in at $1.191 billion... ► Artikel lesen | |
| EYEPOINT | 14,670 | 0,00 % | EyePoint Pharmaceuticals, Inc.: EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026 | ||
| LIGAND PHARMACEUTICALS | 166,00 | +9,21 % | Expert Outlook: Ligand Pharmaceuticals Through The Eyes Of 5 Analysts | ||
| JAZZ PHARMACEUTICALS | 159,55 | -0,78 % | Jazz Pharmaceuticals Plc Q4 Profit Climbs | WASHINGTON (dpa-AFX) - Jazz Pharmaceuticals plc (JAZZ) released earnings for its fourth quarter that Increases, from the same period last yearThe company's earnings totaled $203.45 million,... ► Artikel lesen | |
| OPKO HEALTH | 1,020 | 0,00 % | OPKO Health, Inc.: OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results | MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces... ► Artikel lesen | |
| UNITED THERAPEUTICS | 426,00 | -0,02 % | H.C. Wainwright raises United Therapeutics stock price target to $600 | ||
| ROYALTY PHARMA | 39,000 | -0,28 % | Royalty Pharma: TD Cowen hebt Kursziel wegen Wachstumsaussichten auf 50 $ an | ||
| CATALYST PHARMACEUTICALS | 19,425 | -0,49 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3%... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 55,90 | -0,64 % | BridgeBio Pharma, Inc.: BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates | $154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectivelyBridgeBio... ► Artikel lesen | |
| TG THERAPEUTICS | 25,700 | +0,92 % | TG Therapeutics, Inc.: TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance | Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively Target guidance of approximately... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 6,950 | -4,14 % | Corbus Pharmaceuticals Holdings, Inc. - 8-K, Current Report | ||
| SOLIGENIX | 1,180 | +2,61 % | Soligenix Gets Positive EMA Opinion For Orphan Drug Status Of SGX945 |
MEDICUS PHARMA LTD gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von +0,170 (+12,50 %) liegt der Kurs bei 1,530 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICUS PHARMA LTD finden Sie auf Wallstreet Online.